Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Kinugasa

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Nihon Rinsho. Japanese Journal of Clinical Medicine|December 13, 1997
[Sexual dysfunction in the male patients on hemodialysis]E Kinugasa, H Tayama, Y Sato
Clinical Calcium|March 19, 2005
[Pathogenesis of adynamic bone disease]H Ogata, T Ito, E Kinugasa
ASAIO Transactions|July 1, 1991
Endothelin and platelet activating factor. Possible indices for biocompatibility of hemodialysisT Akizawa, E Kinugasa, S Koshikawa
Clinical Nephrology|November 1, 1995
Plasma bradykinin levels during hemodialysis with PAN DX and polysulfone membranes with and without concurrent ACE inhibitorM Wakasa, T Akizawa, E Kinugasa, et al.
Nephron|January 1, 1991
Effects of recombinant human erythropoietin and correction of anemia on platelet function in hemodialysis patientsT Akizawa, E Kinugasa, T Kitaoka, et al.
Clinical Nephrology|April 1, 1983
Phagocytic activity of polymorphonuclear leucocytes in patients with IgA nephropathyM Sato, E Kinugasa, T Ideura, et al.
Artificial Organs|February 1, 1988
Evaluation of beta 2-microglobulin removal with high-performance hemodiafiltrationE Kinugasa, T Akizawa, T Kitaoka, et al.
Kidney International. Supplement|November 14, 1997
Incidence and clinical characteristics of hypoparathyroidism in dialysis patientsT Akizawa, E Kinugasa, T Akiba, et al.
The International Journal of Artificial Organs|October 1, 1992
Nafamostat as anti-coagulant for membrane plasmapheresis in high bleeding risk patientsE Kinugasa, T Akizawa, Y Nakashima, et al.
ASAIO Transactions|July 1, 1991
Changes in endothelial vasoactive substances under recombinant human erythropoietin therapy in hemodialysis patientsK Takayama, T Nagai, E Kinugasa, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Nihon Rinsho. Japanese Journal of Clinical Medicine|December 13, 1997
[Sexual dysfunction in the male patients on hemodialysis]E Kinugasa, H Tayama, Y Sato
Clinical Calcium|March 19, 2005
[Pathogenesis of adynamic bone disease]H Ogata, T Ito, E Kinugasa
ASAIO Transactions|July 1, 1991
Endothelin and platelet activating factor. Possible indices for biocompatibility of hemodialysisT Akizawa, E Kinugasa, S Koshikawa
Clinical Nephrology|November 1, 1995
Plasma bradykinin levels during hemodialysis with PAN DX and polysulfone membranes with and without concurrent ACE inhibitorM Wakasa, T Akizawa, E Kinugasa, et al.
Nephron|January 1, 1991
Effects of recombinant human erythropoietin and correction of anemia on platelet function in hemodialysis patientsT Akizawa, E Kinugasa, T Kitaoka, et al.
Clinical Nephrology|April 1, 1983
Phagocytic activity of polymorphonuclear leucocytes in patients with IgA nephropathyM Sato, E Kinugasa, T Ideura, et al.
Artificial Organs|February 1, 1988
Evaluation of beta 2-microglobulin removal with high-performance hemodiafiltrationE Kinugasa, T Akizawa, T Kitaoka, et al.
Kidney International. Supplement|November 14, 1997
Incidence and clinical characteristics of hypoparathyroidism in dialysis patientsT Akizawa, E Kinugasa, T Akiba, et al.
The International Journal of Artificial Organs|October 1, 1992
Nafamostat as anti-coagulant for membrane plasmapheresis in high bleeding risk patientsE Kinugasa, T Akizawa, Y Nakashima, et al.
ASAIO Transactions|July 1, 1991
Changes in endothelial vasoactive substances under recombinant human erythropoietin therapy in hemodialysis patientsK Takayama, T Nagai, E Kinugasa, et al.
Pageof 3